{"title":"人工智能辅助视频结肠镜检查对溃疡性结肠炎的疾病监测:前瞻性研究","authors":"Noriyuki Ogata, Yasuharu Maeda, Masashi Misawa, Kento Takenaka, Kaoru Takabayashi, Marietta Iacucci, Takanori Kuroki, Kazumi Takishima, Keisuke Sasabe, Yu Niimura, Jiro Kawashima, Yushi Ogawa, Katsuro Ichimasa, Hiroki Nakamura, Singo Matsudaira, Seiko Sasanuma, Takemasa Hayashi, Kunihiko Wakamura, Hideyuki Miyachi, Toshiyuki Baba, Yuichi Mori, Kazuo Ohtsuka, Haruhiko Ogata, Shin-Ei Kudo","doi":"10.1093/ecco-jcc/jjae080","DOIUrl":null,"url":null,"abstract":"<p><strong>Backgrounds and aims: </strong>The Mayo endoscopic subscore (MES) is the most popular endoscopic disease activity measure of ulcerative colitis (UC). Artificial intelligence (AI)-assisted colonoscopy is expected to reduce diagnostic variability among endoscopists. However, no study has been conducted to ascertain whether AI-based MES assignments can help predict clinical relapse, nor has AI been verified to improve the diagnostic performance of non-specialists.</p><p><strong>Methods: </strong>This open-label, prospective cohort study enrolled 110 patients with UC in clinical remission. The AI algorithm was developed using 74713 images from 898 patients who underwent colonoscopy at three centers. Patients were followed up after colonoscopy for 12 months, and clinical relapse was defined as a partial Mayo score >2. A multi-video, multi-reader analysis involving 124 videos was conducted to determine whether the AI system reduced the diagnostic variability among six non-specialists.</p><p><strong>Results: </strong>The clinical relapse rate for patients with AI-based MES = 1 (24.5% [12/49]) was significantly higher (log-rank test, P = 0.01) than that for patients with AI-based MES = 0 (3.2% [1/31]). Relapse occurred during the 12-month follow-up period in 16.2% (13/80) of patients with AI-based MES = 0 or 1 and 50.0% (10/20) of those with AI-based MES = 2 or 3 (log-rank test, P = 0.03). Using AI resulted in better inter- and intra-observer reproducibility than endoscopists alone.</p><p><strong>Conclusions: </strong>Colonoscopy using the AI-based MES system can stratify the risk of clinical relapse in patients with UC and improve the diagnostic performance of non-specialists.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Artificial intelligence-assisted video colonoscopy for disease monitoring of ulcerative colitis: A prospective study.\",\"authors\":\"Noriyuki Ogata, Yasuharu Maeda, Masashi Misawa, Kento Takenaka, Kaoru Takabayashi, Marietta Iacucci, Takanori Kuroki, Kazumi Takishima, Keisuke Sasabe, Yu Niimura, Jiro Kawashima, Yushi Ogawa, Katsuro Ichimasa, Hiroki Nakamura, Singo Matsudaira, Seiko Sasanuma, Takemasa Hayashi, Kunihiko Wakamura, Hideyuki Miyachi, Toshiyuki Baba, Yuichi Mori, Kazuo Ohtsuka, Haruhiko Ogata, Shin-Ei Kudo\",\"doi\":\"10.1093/ecco-jcc/jjae080\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Backgrounds and aims: </strong>The Mayo endoscopic subscore (MES) is the most popular endoscopic disease activity measure of ulcerative colitis (UC). Artificial intelligence (AI)-assisted colonoscopy is expected to reduce diagnostic variability among endoscopists. However, no study has been conducted to ascertain whether AI-based MES assignments can help predict clinical relapse, nor has AI been verified to improve the diagnostic performance of non-specialists.</p><p><strong>Methods: </strong>This open-label, prospective cohort study enrolled 110 patients with UC in clinical remission. The AI algorithm was developed using 74713 images from 898 patients who underwent colonoscopy at three centers. Patients were followed up after colonoscopy for 12 months, and clinical relapse was defined as a partial Mayo score >2. A multi-video, multi-reader analysis involving 124 videos was conducted to determine whether the AI system reduced the diagnostic variability among six non-specialists.</p><p><strong>Results: </strong>The clinical relapse rate for patients with AI-based MES = 1 (24.5% [12/49]) was significantly higher (log-rank test, P = 0.01) than that for patients with AI-based MES = 0 (3.2% [1/31]). Relapse occurred during the 12-month follow-up period in 16.2% (13/80) of patients with AI-based MES = 0 or 1 and 50.0% (10/20) of those with AI-based MES = 2 or 3 (log-rank test, P = 0.03). Using AI resulted in better inter- and intra-observer reproducibility than endoscopists alone.</p><p><strong>Conclusions: </strong>Colonoscopy using the AI-based MES system can stratify the risk of clinical relapse in patients with UC and improve the diagnostic performance of non-specialists.</p>\",\"PeriodicalId\":94074,\"journal\":{\"name\":\"Journal of Crohn's & colitis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Crohn's & colitis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/ecco-jcc/jjae080\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Crohn's & colitis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ecco-jcc/jjae080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:梅奥内镜子评分(MES)是溃疡性结肠炎(UC)最常用的内镜疾病活动度测量方法。人工智能(AI)辅助结肠镜检查有望减少内镜医师之间的诊断差异。然而,目前还没有研究确定基于人工智能的 MES 作业是否有助于预测临床复发,也没有证实人工智能能提高非专科医生的诊断能力:这项开放标签、前瞻性队列研究共招募了 110 名临床缓解期 UC 患者。人工智能算法是利用在三个中心接受结肠镜检查的 898 名患者的 74713 张图像开发的。对结肠镜检查后的患者进行了为期12个月的随访,临床复发的定义是部分梅奥评分>2。研究人员对124个视频进行了多视频、多阅片人分析,以确定人工智能系统是否减少了6名非专科医生之间的诊断差异:基于人工智能的 MES = 1 患者的临床复发率(24.5% [12/49])明显高于基于人工智能的 MES = 0 患者的临床复发率(3.2% [1/31])(对数秩检验,P = 0.01)。在为期 12 个月的随访期间,人工智能 MES = 0 或 1 的患者中有 16.2%(13/80)复发,而人工智能 MES = 2 或 3 的患者中有 50.0%(10/20)复发(对数秩检验,P = 0.03)。与单纯的内镜医师相比,使用人工智能可提高观察者之间和观察者内部的可重复性:结论:使用基于人工智能的 MES 系统进行结肠镜检查可对 UC 患者的临床复发风险进行分层,并提高非专科医生的诊断能力。
Artificial intelligence-assisted video colonoscopy for disease monitoring of ulcerative colitis: A prospective study.
Backgrounds and aims: The Mayo endoscopic subscore (MES) is the most popular endoscopic disease activity measure of ulcerative colitis (UC). Artificial intelligence (AI)-assisted colonoscopy is expected to reduce diagnostic variability among endoscopists. However, no study has been conducted to ascertain whether AI-based MES assignments can help predict clinical relapse, nor has AI been verified to improve the diagnostic performance of non-specialists.
Methods: This open-label, prospective cohort study enrolled 110 patients with UC in clinical remission. The AI algorithm was developed using 74713 images from 898 patients who underwent colonoscopy at three centers. Patients were followed up after colonoscopy for 12 months, and clinical relapse was defined as a partial Mayo score >2. A multi-video, multi-reader analysis involving 124 videos was conducted to determine whether the AI system reduced the diagnostic variability among six non-specialists.
Results: The clinical relapse rate for patients with AI-based MES = 1 (24.5% [12/49]) was significantly higher (log-rank test, P = 0.01) than that for patients with AI-based MES = 0 (3.2% [1/31]). Relapse occurred during the 12-month follow-up period in 16.2% (13/80) of patients with AI-based MES = 0 or 1 and 50.0% (10/20) of those with AI-based MES = 2 or 3 (log-rank test, P = 0.03). Using AI resulted in better inter- and intra-observer reproducibility than endoscopists alone.
Conclusions: Colonoscopy using the AI-based MES system can stratify the risk of clinical relapse in patients with UC and improve the diagnostic performance of non-specialists.